title: [Effect of traxanox sodium on inflammatory response].
abstract: Traxanox was inactive against classic acute and subacute inflammation models such as carrageenin paw edema, UV erythema, 6-hr Evans blue-carrageenin (E-C) pleurisy and cotton pellet granuloma formation, and it failed to inhibit the production of prostaglandin E2 and a slow reacting substance from rat peritoneal leucocytes which phagocytize killed bacteria in vitro. On the other hand, traxanox inhibited the anaphylactoid reaction and decreased the pleural fluid in 24-hr E-C pleurisy. Traxanox (100 mg/kg, p.o.) also showed a tendency to suppress dextran edema and cotton pellet granuloma formation in adjuvant arthritis (AA) in rats. In experimental models of delayed type hypersensitivity (DTH), traxanox (100 mg/kg, p.o.) inhibited the accumulation of the exudate and the leucocyte migration in B. pertussis-induced pleurisy in rats. Traxanox (50 mg/kg) did not show any effect on AA in Lewis rats when administered orally for 21 days after the adjuvant inoculation, but the combined administration of traxanox with hydrocortisone (10 mg/kg, p.o.) or indomethacin (0.25 mg/kg, p.o.) resulted in a synergistic inhibition of AA. When the administration of traxanox was started 21 days before the adjuvant inoculation, it inhibited AA in a dose-dependent manner (50-100 mg/kg, p.o.). On the other hand, traxanox (100 mg/kg, p.o.) enhanced the concanavalin A-induced DTH-like skin reaction in guinea pigs. These results indicate that the mode of action of traxanox on inflammatory responses resembles that of D-penicillamine or levamisole, so that it may prove to be clinically effective in treating rheumatoid arthritis.
authors.forename: M
authors.initials: M
authors.lastname: Terasawa
authors.forename: T
authors.initials: T
authors.lastname: Imayoshi
authors.forename: Y
authors.initials: Y
authors.lastname: Maruyama
authors.forename: C
authors.initials: C
authors.lastname: Abe
mesh_terms: D000707:Anaphylaxis / Q000188:drug therapy; D000818:Animals; D000893:Anti-Inflammatory Agents; D001169:Arthritis, Experimental / Q000188:drug therapy; D012898:Autacoids / Q000096:biosynthesis; D002867:Chromones / Q000627:therapeutic use*; D015232:Dinoprostone; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed / Q000188:drug therapy; D007166:Immunosuppressive Agents; D066298:In Vitro Techniques; D007249:Inflammation / Q000188:drug therapy; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D010998:Pleurisy / Q000188:drug therapy; D011458:Prostaglandins E / Q000096:biosynthesis; D051381:Rats; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains
chemical_list: D000893:Anti-Inflammatory Agents; D012898:Autacoids; D002867:Chromones; D007166:Immunosuppressive Agents; D011458:Prostaglandins E; C020178:traxanox; D015232:Dinoprostone